A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
A Phase 3, 24-week, Randomized, Double-blind, Parallel-group Bayesian Dynamic Borrowing Study Comparing the Efficacy, Safety, Tolerability and Pharmacokinetics of FF/UMEC/VI With FF/VI in 12-17-year-old Participants With Inadequately Controlled Asthma on Stable Maintenance Therapy With ICS/LABA
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Asthma and is currently actively recruiting participants. GlaxoSmithKline leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Aug 2023 — Feb 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aventura, United States , Bakersfield, United States , Birmingham, United States , Buenos Aires, Argentina , Charleston, United States , Cheongju Chungcheongbuk-do, South Korea , Cincinnati, United States , Cleveland, United States , Colorado Springs, United States , Columbia, United States and 26 more locations